Инфекция Helicobacter pylori: варианты внежелудочной локализации микроорганизма

Статья представляет собой комплексный обзор, систематизирующий современные данные о внежелудочных проявлениях при инфицировании Helicobacter pylori. Помимо хорошо изученной связи микроба с патологией желудочно-кишечного тракта (гастрит, язва, рак желудка), H. pylori может персистировать в других органах и оказывать системное негативное влияние на организм. В статье разбираются четыре основных пути развития внежелудочных проявлений при персистенции микроорганизма: прямая миграция бактерии и колонизация других органов, развитие хронического системного воспаления и эндотоксинемии, феномен молекулярной мимикрии, ведущий к аутоиммунным реакциям, опосредованное влияние через нарушение микробиоты кишечника (дисбиоз). Подчеркивается, что хеликобактериоз и дисбиоз кишечника являются звеньями одной патогенетической цепи. Эрадикационная терапия может усугублять дисбиоз, что указывает на потенциальную пользу применения пробиотиков.

Helicobacter pylori, микробиота, эрадикация, хеликобактериоз, пробиотики, инфекция, онкология, желудочно-кишечный тракт

1. Isakov V.A., Domaradsky I.V. [Helicobacter pylori]. Moscow. Medpraktika, 2003. 412 p. (in Russ.)@@ Исаков В.А., Домарадский И.В. Хеликобактериоз. - М.: Медпрактика, 2003. - 412 с.

2. Whary M.T., Fox J.G. Detection, eradication, and research implications of Helicobacter infections in laboratory rodents. Lab Anim (NY). 2006 Jul-Aug;35(7):25-7, 30-6. doi: 10.1038/laban0706-25.

3. Alvarado C.G., Kocsis A.G., Hart M.L., Crim M.J., Myles M.H., Franklin C.L. Pathogenicity of Helicobacter ganmani in mice susceptible and resistant to infection with H. hepaticus.Comp Med. 2015 Feb;65(1):15-22.

4. Andersen L.P. New Helicobacter species in humans. Dig Dis. 2001;19(2):112-5. doi: 10.1159/000050664.

5. Robertson B.R., O’Rourke J.L., Vandamme P., On S.L., Lee A. Helicobacter ganmani sp. nov., a urease-negative anaerobe isolated from the intestines of laboratory mice.Int J Syst Evol Microbiol. 2001 Sep;51(Pt 5):1881-1889. doi: 10.1099/00207713-51-5-1881.

6. Krzyżek P., Gościniak G. Oral Helicobacter pylori: Interactions with host and microbial flora of the oral cavity. Dent Med Probl. 2018 Jan-Mar;55(1):75-82. doi: 10.17219/dmp/81259.

7. Lukina G.I. [The state of periodontal tissues in patients with diseases of the upper gastrointestinal tract]. Proceedings of the XXI and XXIV All-Russian scientific and practical conferences. Moscow. 2010. pp. 71-73. (in Russ.)@@ Лукина Г.И. Состояние тканей пародонта у пациентов с заболеваниями верхних отделов пищеварительного тракта //Материалы ХХІ и XXIV Всероссийских научно-практических конференций. - М., 2010.-С. 71-73

8. Al Sayed A., Anand P.S., Kamath K.P., Patil S., Preethanath R.S., Anil S. Oral Cavity as an Extragastric Reservoir of Helicobacter pylori. ISRN Gastroenterol. 2014 Feb 20;2014:261369. doi: 10.1155/2014/261369.

9. Kosyuga S. Yu., Varvanina S.E. Features of the manifestation of Helicobacter pylori on the oral mucosa. Modern Problems of Science and Education. 2015, No. 1-1. (in Russ.)@@ Косюга С.Ю., Варванина С.Э. Особенности проявления Helicobacter pylori на слизистой оболочке полости рта. Современные проблемы науки и образования. - 2015. - № 1-1

10. Yee JK. Helicobacter pylori colonization of the oral cavity: A milestone discovery. World J Gastroenterol. 2016 Jan 14;22(2):641-8. doi: 10.3748/wjg.v22.i2.641.

11. Uspensky Yu.P., Suvorov A.N., Baryshnikova N.V. [Helicobacter pylori infection in clinical practice]. St. Petersburg: InformMed. 2011. 572 p. (in Russ.)@@ Успенский Ю.П., Суворов А.Н., Барышникова Н.В. Инфекция Helicobacter pylori в клинической практике. СПб: ИнформМед, 2011. - 572 с.

12. Gorbacheva I.A., Uspensky Yu.P., Baryshnikova N.V., Fominykh Yu.A., Orekhova L. Yu. [Helicobacter pylori infection and oral diseases (methodological recommendations)]. St. Petersburg, 2015. 49 p. (in Russ.)@@ Горбачева И.А., Успенский Ю.П., Барышникова Н.В., Фоминых Ю.А., Орехова Л.Ю. Инфекция Helicobacter pylori и заболевания полости рта (методические рекомендации). СПб, 2015. - 49 с.

13. Anisimova T.A., Larionova D.V. The role of Helicobacter pylori in the development of oral diseases. Electronic scientific journal. Biology and integrative medicine. 2024; 5 (70): 56-64. (in Russ.)@@ Анисимова Т.А., Ларионова Д.В. Роль Helicobacter pylori в развитии заболеваний полости рта. Электронный научный журнал «Биология и интегративная медицина». 2024; 5 (70): 56-64.

14. Kaspina A.I., Drozhzhina V.A., Kerzikov A.F., Kerzikov O.A. The influence of Helicobacter pylori infection on the condition of the oral mucosa. Scientific and practical journal Institute of Dentistry. 2003; 4 (21):68-69. (in Russ.)@@ Каспина А.И., Дрожжина В.А., Керзиков А.Ф., Керзиков О.А. Влияние инфицирования Helicobacter pylori на состояние слизистой оболочки рта. Научно-практический журнал Институт Стоматологии. 2003; 4 (21):68-69.

15. Lin T.T., Yeh C.T., Wu C.S., Liaw Y.F. Detection and partial sequence analysis of Helicobacter pylori DNA in the bile samples. Dig Dis Sci. 1995 Oct;40(10):2214-9. doi: 10.1007/BF02209009.

16. Leong R.W., Sung J.J. Review article: Helicobacter species and hepatobiliary diseases. Aliment Pharmacol Ther. 2002 Jun;16(6):1037-45. doi: 10.1046/j.1365-2036.2002.01282.x.

17. Starzyñska T., Malfertheiner P. Helicobacter and digestive malignancies. Helicobacter. 2006 Oct;11 Suppl 1:32-5. doi: 10.1111/j.1478-405X.2006.00431.x.

18. Burnens A.P., Stanley J., Morgenstern R., Nicolet J. Gastroenteritis associated with Helicobacter pullorum. Lancet. 1994 Dec 3;344(8936):1569-70. doi: 10.1016/s0140-6736(94)90376-x.

19. Fox J.G., Yan L.L., Dewhirst F.E. et al. Helicobacter bilis sp. nov., a novel Helicobacter species isolated from bile, livers, and intestines of aged, inbred mice. J Clin Microbiol. 1995 Feb;33(2):445-54. doi: 10.1128/jcm.33.2.445-454.1995.

20. Fox J.G., MacGregor J.A., Shen Z., Li X., Lewis R., Dangler C.A.Comparison of methods of identifying Helicobacter hepaticus in B6C3F1 mice used in a carcinogenesis bioassay. J Clin Microbiol. 1998 May;36(5):1382-7. doi: 10.1128/JCM.36.5.1382-1387.1998.

21. Figura N., Vindigni C., Presenti L., Carducci A. New acquisitions in Helicobacter pylori characteristics. Ital J Gastroenterol Hepatol. 1998 Oct;30 Suppl 3: S254-8.

22. Rocha M., Avenaud P., Ménard A. et al. Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut. 2005 Mar;54(3):396-401. doi: 10.1136/gut.2004.042168.

23. Zhang Y., Fan X.G., Chen R., Xiao Z.Q., Feng X.P., Tian X.F., Chen Z.H.Comparative proteome analysis of untreated and Helicobacter pylori-treated HepG2. World J Gastroenterol. 2005 Jun 14;11(22):3485-9. doi: 10.3748/wjg.v11.i22.3485.

24. Silva C.P., Pereira-Lima J.C., Oliveira A.G. et al. Association of the presence of Helicobacter in gallbladder tissue with cholelithiasis and cholecystitis. J Clin Microbiol. 2003 Dec;41(12):5615-8. doi: 10.1128/JCM.41.12.5615-5618.2003.

25. Monstein H.J., Ellnebo-Svedlund K. Molecular typing of Helicobacter pylori by virulence-gene based multiplex PCR and RT-PCR analysis. Helicobacter. 2002 Oct;7(5):287-96. doi: 10.1046/j.1523-5378.2002.00099.x.

26. Neri V., Margiotta M., de Francesco V. et al. DNA sequences and proteic antigens of H. pylori in cholecystic bile and tissue of patients with gallstones. Aliment Pharmacol Ther. 2005 Oct 15;22(8):715-20. doi: 10.1111/j.1365-2036.2005.02644.x.

27. Chen W., Li D., Cannan R.J., Stubbs R.S.Common presence of Helicobacter DNA in the gallbladder of patients with gallstone diseases and controls. Dig Liver Dis. 2003 Apr;35(4):237-43. doi: 10.1016/s1590-8658(03)00060-4.

28. Isaeva G. Sh., Abuzarova E.R., Valeeva Iu.V., Pozdeev O.K., Murav’eva E.V. [Helicobacter pylori in patients with disorders of hepatobiliary system]. Zh Mikrobiol Epidemiol Immunobiol. 2009 Mar-Apr;(2):96-101.Russian. PMID: 19459487.

29. Roe I.H., Kim J.T., Lee H.S., Lee J.H. Detection of Helicobacter DNA in bile from bile duct diseases. J Korean Med Sci. 1999 Apr;14(2):182-6. doi: 10.3346/jkms.1999.14.2.182.

30. Avenaud P., Marais A., Monteiro L., Le Bail B., Bioulac Sage P., Balabaud C., Mégraud F. Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma. Cancer. 2000 Oct 1;89(7):1431-9.

31. Myung S.J., Kim M.H., Shim K.N. et al. Detection of Helicobacter pylori DNA in human biliary tree and its association with hepatolithiasis. Dig Dis Sci. 2000 Jul;45(7):1405-12. doi: 10.1023/a:1005572507572. PMID: 10961722.

32. Nilsson H.O., Taneera J., Castedal M., Glatz E., Olsson R., Wadström T. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. J Clin Microbiol. 2000 Mar;38(3):1072-6. doi: 10.1128/JCM.38.3.1072-1076.2000.

33. Leong R.W., Chan F.K., Sung J.J. Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Approaching the end of the controversy in the new millennium, or room for more debate? J Gastroenterol. 2001 Nov;36(11):731-9. doi: 10.1007/s005350170014.

34. Apostolov E., Al-Soud W.A., Nilsson I. et al. Helicobacter pylori and other Helicobacter species in gallbladder and liver of patients with chronic cholecystitis detected by immunological and molecular methods. Scand J Gastroenterol. 2005 Jan;40(1):96-102. doi: 10.1080/00365520410009546.

35. Pirouz T., Zounubi L., Keivani H., Rakhshani N., Hormazdi M. Detection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method. Dig Dis Sci. 2009 Jul;54(7):1456-9. doi: 10.1007/s10620-008-0522-5.

36. Keenan J.I., Beaugie C.R., Jasmann B., Potter H.C., Collett J.A., Frizelle F.A. Helicobacter species in the human colon. Colorectal Dis. 2010 Jan;12(1):48-53. doi: 10.1111/j.1463-1318.2008.01672.x.

37. Avalueva E.B., Serkova M. Yu., Sitkin S.I. Helicobacter pylori. The survival strategy of a commensal symbiont in the Homo sapiens population. Experimental and Clinical Gastroenterology. 2021;(9):102-108. (In Russ.) doi: 10.31146/1682-8658-ecg-193-9-102-108.@@ Авалуева Е.Б., Серкова М.Ю., Ситкин С.И. Helicobacter pylori. Стратегия выживания комменсального симбионта в популяции Homo sapiens. Экспериментальная и клиническая гастроэнтерология. 2021;193(9): 102-108. doi: 10.31146/1682-8658-ecg-193-9-102-108.

38. Dash N.R., Khoder G., Nada A.M., Al Bataineh M.T. Exploring the impact of Helicobacter pylori on gut microbiome composition. PLoS One. 2019; 14: e0218274. doi: 10.1371/journal.pone.0218274.

39. Zhao Y.S., Wang F., Chang D., Han B., You D.Y. Meta-analysis of different test indicators: Helicobacter pylori infection and the risk of colorectal cancer.Int J Colorectal Dis. 2008 Sep;23(9):875-82. doi: 10.1007/s00384-008-0479-z.

40. Robertson D.J., Sandler R.S., Ahnen D.J., Greenberg E.R., Mott L.A., Cole B.F., Baron J.A. Gastrin, Helicobacter pylori, and colorectal adenomas. Clin Gastroenterol Hepatol. 2009 Feb;7(2):163-7. doi: 10.1016/j.cgh.2008.09.006.

41. Soylu A., Ozkara S., Alis H., Dolay K., Kalayci M., Yasar N., Kumbasar A.B. Immunohistochemical testing for Helicobacter Pylori existence in neoplasms of the colon. BMC Gastroenterol. 2008 Aug 14;8:35. doi: 10.1186/1471-230X-8-35.

42. Zumkeller N., Koenig W., Hoffmann M.M., Kolb H., Brenner H., Rothenbacher D. Helicobacter pylori seropositive subjects do not show a pronounced systemic inflammatory response even in the presence of the interleukin-1 receptor antagonist gene polymorphism. Epidemiol Infect. 2005 Jun;133(3):569-72. doi: 10.1017/s095026880400319x.

43. Fujimori S. Asymptomatic small intestinal ulcerative lesions: Obesity and Helicobacter pylori are likely to be risk factors. World J Gastroenterol. 2021 Jul 28;27(28):4484-4492. doi: 10.3748/wjg.v27.i28.4484.

44. Mizuno S., Morita Y., Inui T. et al. Helicobacter pylori infection is associated with colon adenomatous polyps detected by high-resolution colonoscopy.Int J Cancer. 2005 Dec 20;117(6):1058-9. doi: 10.1002/ijc.21280.

45. Sitkin S., Lazebnik L., Avalueva E., Kononova S., Vakhitov T. Gastrointestinal microbiome and Helicobacter pylori: Eradicate, leave it as it is, or take a personalized benefit-risk approach? World J Gastroenterol. 2022; 28(7): 766-774. doi: 10.3748/wjg.v28.i7.7.

46. Uspenskiy Yu.P., Baryshnikova N.V., Suvorov A.N., Svarval A.V. Helicobacter pylori infection and inflammatory bowel diseases.Russian Journal of Infection and Immunity = Infektsiya i immunitet. 2021, vol. 11, no. 1, pp. 68-78. doi: 10.15789/2220-7619-HPI-1510.@@ Успенский Ю.П., Барышникова Н.В., Суворов А.Н., Сварваль А.В. Инфекция Helicobacter pylori и воспалительные заболевания кишечника. Инфекция и иммунитет. 2021. Т. 11, № 1. С. 68-78. doi: 10.15789/2220-7619-HPI-1510.

47. Engler D.B., Leonardi I., Hartung M.L., Kyburz A., Spath S., Becher B., Rogler G., Müller A. Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18. Inflamm Bowel Dis. 2015; 21: 854-861. doi: 10.1097/MIB.0000000000000318.

48. Sitkin S., Lazebnik L., Avalueva E., Kononova S., Vakhitov T. Gastrointestinal microbiome and Helicobacter pylori: Eradicate, leave it as it is, or take a personalized benefit-risk approach? World J Gastroenterol. 2022; 28(7): 766-774. doi: 10.3748/wjg.v28.i7.766.

49. Papamichael K., Konstantopoulos P., Mantzaris G.J. Helicobacter pylori infection and inflammatory bowel disease: is there a link? World J Gastroenterol. 2014; 20: 6374-6385. doi: 10.3748/wjg.v20.i21.6374.

50. Ozdek A., Cirak M.Y., Samim E., Bayiz U., Safak M.A., Turet S. A possible role of Helicobacter pylori in chronic rhinosinusitis: a preliminary report. Laryngoscope. 2003 Apr;113(4):679-82. doi: 10.1097/00005537-200304000-00018.

51. Cellini L., Allocati N., Dainelli B. Failure to detect Helicobacter pylori in nasal mucus in H pylori positive dyspeptic patients. J Clin Pathol. 1995 Nov;48(11):1072-3. doi: 10.1136/jcp.48.11.1072.

52. Kim H.Y., Dhong H.J., Chung S.K., Chung K.W., Chung Y.J., Jang K.T.Intranasal Helicobacter pylori colonization does not correlate with the severity of chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2007 Mar;136(3):390-5. doi: 10.1016/j.otohns.2006.10.015.

53. Ozyurt M., Gungor A., Ergunay K., Cekin E., Erkul E., Haznedaroglu T. Real-time PCR detection of Helicobacter pylori and virulence-associated cagA in nasal polyps and laryngeal disorders. Otolaryngol Head Neck Surg. 2009 Jul;141(1):131-5. doi: 10.1016/j.otohns.2009.04.005.

54. Cvorovic L., Brajovic D., Strbac M., Milutinovic Z., Cvorovic V. Detection of Helicobacter pylori in nasal polyps: preliminary report. J Otolaryngol Head Neck Surg. 2008 Apr;37(2):192-5. PMID: 19128611

55. Ozcan C., Polat A., Otağ F., Görür K. Does Helicobacter pylori play a role in etiology of nasal polyposis? Auris Nasus Larynx. 2009 Aug;36(4):427-30. doi: 10.1016/j.anl.2008.09.007.

56. Eyigor M., Eyigor H., Gultekin B., Aydin N. Detection of Helicobacter pylori in adenotonsiller tissue specimens by rapid urease test and polymerase chain reaction. Eur Arch Otorhinolaryngol. 2009 Oct;266(10):1611-3. doi: 10.1007/s00405-008-0903-6.

57. Lukes P., Astl J., Pavlík E., Potuzníková B., Sterzl I., Betka J. Helicobacter pylori in tonsillar and adenoid tissue and its possible role in oropharyngeal carcinogenesis. Folia Biol (Praha). 2008;54(2):33-9. PMID: 18498719.

58. Bulut Y., Agacayak A., Karlidag T., Toraman Z.A., Yilmaz M. Association of cagA+ Helicobacter pylori with adenotonsillar hypertrophy. Tohoku J Exp Med. 2006 Jul;209(3):229-33. doi: 10.1620/tjem.209.229.

59. Vayisoglu Y., Ozcan C., Polat A., Delialioglu N., Gorur K. Does Helicobacter pylori play a role in the development of chronic adenotonsillitis? Int J Pediatr Otorhinolaryngol. 2008 Oct;72(10):1497-501. doi: 10.1016/j.ijporl.2008.06.018.

60. Zhang J.P., Peng Z.H., Zhang J., Zhang X.H., Zheng Q.Y. Helicobacter pylori infection in the pharynx of patients with chronic pharyngitis detected with TDI-FP and modified Giemsa stain. World J Gastroenterol. 2006 Jan 21;12(3):468-72. doi: 10.3748/wjg.v12.i3.468.

61. Aladag I., Bulut Y., Guven M., Eyibilen A., Yelken K. Seroprevalence of Helicobacter pylori infection in patients with chronic nonspecific pharyngitis: preliminary study. J Laryngol Otol. 2008 Jan;122(1):61-4. doi: 10.1017/S0022215107006743.

62. Kaptan Z.K., Emir H., Uzunkulaoğlu H. et al. Determination of Helicobacter pylori in patients with chronic nonspecific pharyngitis. Laryngoscope. 2009 Aug;119(8):1479-83. doi: 10.1002/lary.20253.

63. Aladag I., Eyibilen A., Guven M., Erkokmaz U. Effects of helicobacter pylori eradication on chronic nonspecific pharyngeal symptoms. J Otolaryngol Head Neck Surg. 2008 Oct;37(5):623-7. PMID: 19128666.

64. Tiba M., Fawaz S., Osman H. Helicobacter pylori and its role in vocal folds’ minimal lesions. Clin Respir J. 2010 Oct;4(4):237-40. doi: 10.1111/j.1752-699X.2009.00182.x.

65. Oridate N., Takeda H., Asaka M., Nishizawa N., Mesuda Y., Mori M., Furuta Y., Fukuda S. Acid-suppression therapy offers varied laryngopharyngeal and esophageal symptom relief in laryngopharyngeal reflux patients. Dig Dis Sci. 2008 Aug;53(8):2033-8. doi: 10.1007/s10620-007-0114-9.

66. Titiz A., Ozcakir O., Ceyhan S., Yilmaz Y.F., Unal A., Akyon Y. The presence of Helicobacter pylori in the larynx pathologies. Auris Nasus Larynx. 2008 Dec;35(4):534-8. doi: 10.1016/j.anl.2007.12.004.

67. Grbesa I., Marinkovic M., Ivkic M. et al. Loss of imprinting of IGF2 and H19, loss of heterozygosity of IGF2R and CTCF, and Helicobacter pylori infection in laryngeal squamous cell carcinoma. J Mol Med (Berl). 2008 Sep;86(9):1057-66. doi: 10.1007/s00109-008-0369-4.

68. Rezaii J., Tavakoli H., Esfandiari K. et al. Association between Helicobacter pylori infection and laryngo-hypopharyngeal carcinoma: a case-control study and review of the literature. Head Neck. 2008 Dec;30(12):1624-7. doi: 10.1002/hed.20918.

69. Zhuo X.L., Wang Y., Zhuo W.L., Zhang X.Y. Possible association of Helicobacter pylori infection with laryngeal cancer risk: an evidence-based meta-analysis. Arch Med Res. 2008 Aug;39(6):625-8. doi: 10.1016/j.arcmed.2008.04.008.

70. Afsar B., Ozdemir F.N., Elsurer R., Sezer S. Helicobacter pylori infection may increase renal resistive index. Med Hypotheses. 2007;69(4):956-7. doi: 10.1016/j.mehy.2007.01.061.

71. Pietroiusti A., Giuliano M., Magrini A., Bergamaschi A., Galante A. Cytotoxin-associated gene A strains of Helicobacter pylori represent a risk factor for the development of microalbuminuria in type 2 diabetes. Diabetes Care. 2006 Jun;29(6):1399-401. doi: 10.2337/dc06-0404.

72. Kanbay M., Kasapoglu B., Akcay A. An occult risk factor for proteinuria: Helicobacter pylori infection. Med Hypotheses. 2007;69(3):709-10. doi: 10.1016/j.mehy.2007.01.010.

73. Sugimoto T., Furukawa T., Maeda T., Somura M., Uzu T., Kashiwagi A. Marked reduction of proteinuria after eradication of gastric Helicobacter pylori infection in a patient with membranous nephropathy: coincidental or associated? Intern Med. 2007;46(17):1483-4. doi: 10.2169/internalmedicine.46.0200.

74. Moyaert H., Franceschi F., Roccarina D., Ducatelle R., Haesebrouck F., Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection: other Helicobacters. Helicobacter. 2008 Oct;13 Suppl 1:47-57. doi: 10.1111/j.1523-5378.2008.00634.x.

75. Karatas O.F., Bayrak O., Cimentepe E., Unal D. An occult risk factor for chronic prostatitis: Helicobacter pylori. Med Hypotheses. 2007;69(4):963-4. doi: 10.1016/j.mehy.2007.01.030.

76. Shousha S., Arnaout A.H., Abbas S.H., Parkins R.A. Antral Helicobacter pylori in patients with chronic renal failure. J Clin Pathol. 1990 May;43(5):397-9. doi: 10.1136/jcp.43.5.397.

77. Jaspersen D., Fassbinder W., Heinkele P. et al. Significantly lower prevalence of Helicobacter pylori in uremic patients than in patients with normal renal function. J Gastroenterol. 1995 Oct;30(5):585-8. doi: 10.1007/BF02367783.

78. Abdulrahman I.S., Al-Mueilo S.H., Ismail M.H., Yasawy M.I., Al-Qahtani F.N., Al-Qorain A.A. Does Helicobacter pylori infection in chronic renal failure increase the risk of gastroduodenal lesions? A prospective study. Saudi J Gastroenterol. 2004 May;10(2):78-85. PMID: 19861830.

79. Korzonek M., Szymaniak L., Giedrys-Kalemba S., Ciechanowski K. Czy nalezy leczyć zakazenie Helicobacter pylori u chorych w okresie skrajnej niewydolności nerek i po przeszczepieniu nerek? [Is it necessary to treat Helicobacter pylori infection in patients with end-stage renal failure and in renal transplant recipients?]. Pol Arch Med Wewn. 2004 Mar;111(3):297-304. Polish. PMID: 15230210.

80. Khedmat H., Ahmadzad-Asl M., Amini M., Lessan-Pezeshki M., Einollahi B., Pourfarziani V., Naseri M.H., Davoudi F. Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. Transplant Proc. 2007 May;39(4):1003-7. doi: 10.1016/j.transproceed.2007.03.034.

81. Sugimoto M., Sakai K., Kita M., Imanishi J., Yamaoka Y. Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int. 2009 Jan;75(1):96-103. doi: 10.1038/ki.2008.508.

82. Sugimoto M., Yamaoka Y. Review of Helicobacter pylori infection and chronic renal failure. Ther Apher Dial. 2011 Feb;15(1):1-9. doi: 10.1111/j.1744-9987.2010.00851.x.

83. Loffeld R.J., Peltenburg H.G., vd Oever H., Stobberingh E. Prevalence of Helicobacter pylori antibodies in patients on chronic intermittent haemodialysis. Nephron. 1991;59(2):250-3. doi: 10.1159/000186560.

84. Luzza F., Imeneo M., Maletta M. et al. Helicobacter pylori-specific IgG in chronic haemodialysis patients: relationship of hypergastrinaemia to positive serology. Nephrol Dial Transplant. 1996 Jan;11(1):120-4. PMID: 8649619.

85. Fabrizi F., Martin P. Helicobacter pylori infection in patients with end-stage renal disease.Int J Artif Organs. 2000 Mar;23(3):157-64. PMID: 10795659.

86. Asl M.K., Nasri H. Prevalence of Helicobacter pylori infection in maintenance hemodialysis patients with non-ulcer dyspepsia. Saudi J Kidney Dis Transpl. 2009 Mar;20(2):223-6. PMID: 19237808.

87. Novikova V.P., Baryshnikova N.V., Uspensky Yu.P., Tomsky K.A. [Determination of microbial markers in blood and urine after successful eradication of Helicobacter pylori].Russian Journal of Gastroenterology, Hepatology, Proctology. Proceedings of the Nineteenth Russian Gastroenterological Week, 2013 September 30 - October 2; 42.@@ Новикова В.П., Барышникова Н.В., Успенский Ю.П., Томский К.А. Определение микробных маркеров в крови и моче после успешной эрадикации Helicobacter pylori. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. Материалы Девятнадцатой Российской гастролоэнтерологической недели, 30 сентября - 2 октября 2013 г., Москва. - 2013; 42.

88. Aiello A.E., Diez-Roux A., Noone A.M., Ranjit N., Cushman M., Tsai M.Y., Szklo M. Socioeconomic and psychosocial gradients in cardiovascular pathogen burden and immune response: the multi-ethnic study of atherosclerosis. Brain Behav Immun. 2009 Jul;23(5):663-71. doi: 10.1016/j.bbi.2008.12.006.

89. Ayada K., Yokota K., Kobayashi K., Shoenfeld Y., Matsuura E., Oguma K. Chronic infections and atherosclerosis. Clin Rev Allergy Immunol. 2009 Aug;37(1):44-8. doi: 10.1007/s12016-008-8097-7.

90. Pellicano R., Franceschi F., Saracco G., Fagoonee S., Roccarina D., Gasbarrini A. Helicobacters and extragastric diseases. Helicobacter. 2009 Sep;14 Suppl 1:58-68. doi: 10.1111/j.1523-5378.2009.00699.x.

91. Longo-Mbenza B. Helicobacter pylori and atherosclerosis: can current data be useful for clinical practice? Int J Cardiol. 2009 Jul 10;135(3): e76-7. doi: 10.1016/j.ijcard.2008.04.039.

92. Suzuki H., Suzuki M., Imaeda H., Hibi T. Helicobacter pylori and microcirculation. Microcirculation. 2009 Oct;16(7):547-58. doi: 10.1080/10739680902949953.

93. Tamer G.S., Tengiz I., Ercan E., Duman C., Alioglu E., Turk U.O. Helicobacter pylori seropositivity in patients with acute coronary syndromes. Dig Dis Sci. 2009 Jun;54(6):1253-6. doi: 10.1007/s10620-008-0482-9.

94. Figura N., Franceschi F., Santucci A., Bernardini G., Gasbarrini G., Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2010 Sep;15 Suppl 1:60-8. doi: 10.1111/j.1523-5378.2010.00778.x.

95. Ciervo A., Mancini F., Sale P., Russo A., Cassone A. Real-time polymerase chain reaction and laser capture microdissection: an efficient combination tool for Chlamydophila pneumoniae DNA quantification and localization of infection in atherosclerotic lesions.Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):421-8. doi: 10.1177/039463200802100222.

96. Iriz E., Cirak M.Y., Engin E.D., Zor M.H., Erer D., Ozdogan M.E., Turet S., Yener A. Detection of Helicobacter pylori DNA in aortic and left internal mammary artery biopsies. Tex Heart Inst J. 2008;35(2):130-5. PMID: 18612444.

97. Fadeenko G.D. Helicobacter pylori infection: results of a 20-year study of its pathogenicity. Bulletin of Kharkiv National University named after V.N. Karazin. Series Medicine. 2004. No. 7 (614). (in Russ.)@@ Фадеенко Г.Д. Инфекция Helicobacter pylori: итоги 20-летнего изучения ее патогенности. Вестник ХНУ им. В.Н. Каразина. Серия Медицина. 2004. № 7 (614).

98. Ilchenko A.A. Helicobacter spp. and biliary pathology. Experimental and Clinical Gastroenterology. 2008;(8):19-27. (in Russ.)@@ Ильченко А.А. Helicobacter spp. и билиарная патология. Экспериментальная и клиническая гастроэнтерология. 2008;(8):19-27.

99. Cetta F., Montalto G., Gori M., Curia M.C., Cama A., Olschwang S. Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. J Clin Endocrinol Metab. 2000 Jan;85(1):286-92. doi: 10.1210/jcem.85.1.6254.

100. Graham D.Y., Osato M.S., Olson C.A., Zhang J., Figura N. Effect of H. pylori infection and CagA status on leukocyte counts and liver function tests: extra-gastric manifestations of H. pylori infection. Helicobacter. 1998 Sep;3(3):174-8. doi: 10.1046/j.1523-5378.1998.08018.x.

101. Pavlov O.N. Pathogenetic factors of coronary heart disease and Helicobacter pylori infection.Russian Journal of Cardiology. 2012;(2):91-93. (in Russ.)@@ Павлов О.Н. Патогенетические факторы ИБС и инфекции Helicobacter pylori. Российский кардиологический журнал. 2012;(2):91-93.

102. Nikolopoulou A., Tousoulis D., Antoniades C. et al.Common community infections and the risk for coronary artery disease and acute myocardial infarction: evidence for chronic over-expression of tumor necrosis factor alpha and vascular cells adhesion molecule-1.Int J Cardiol. 2008 Nov 12;130(2):246-50. doi: 10.1016/j.ijcard.2007.08.052.

103. Ayada K., Yokota K., Kawahara Y. et al. Immune reactions against elongation factor 2 kinase: specific pathogenesis of gastric ulcer from Helicobacter pylori infection. Clin Dev Immunol. 2009;2009:850623. doi: 10.1155/2009/850623.

104. Szklo M., Ding J., Tsai M.Y., Cushman M., Polak J.F., Lima J., Barr R.G., Sharrett A.R. Individual pathogens, pathogen burden and markers of subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Med (Hagerstown). 2009 Oct;10(10):747-51. doi: 10.2459/JCM.0b013e32832cacab.

105. Honda C., Adachi K., Arima N. et al. Helicobacter pylori infection does not accelerate the age-related progression of arteriosclerosis: a 4-year follow-up study. J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 2): e373-8. doi: 10.1111/j.1440-1746.2008.05343.x.

106. Oldstone M.B. Molecular mimicry and autoimmune disease. Cell. 1987 Sep 11;50(6):819-20. doi: 10.1016/0092-8674(87)90507-1.

107. Kumamoto C.A., Vinces M.D. Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence. Cell Microbiol. 2005 Nov;7(11):1546-54. doi: 10.1111/j.1462-5822.2005.00616.x.

108. Zeuthen L.H., Fink L.N., Frokiaer H. Epithelial cells prime the immune response to an array of gut-derived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor-beta. Immunology. 2008 Feb;123(2):197-208. doi: 10.1111/j.1365-2567.2007.02687.x.

109. Preuner S., Lion T. Towards molecular diagnostics of invasive fungal infections. Expert Rev Mol Diagn. 2009 Jul;9(5):397-401. doi: 10.1586/erm.09.27.

110. Bastidas R.J., Heitman J., Cardenas M.E. The protein kinase Tor1 regulates adhesin gene expression in Candida albicans. PLoS Pathog. 2009 Feb;5(2): e1000294. doi: 10.1371/journal.ppat.1000294.

111. Baryshnikova N.V., Efficiency of probiotic therapy in correction of intestinal microbiocenosis disorders in patients with chronic gastroduodenitis associated with Helicobacter pylori. Bulletin of the I.I. Mechnikov St. Petersburg State Medical Academy. 2006; (2): 89-92. (in Russ.)@@ Барышникова Н.В., Эффективность пробиотической терапии в коррекции нарушений микробиоценоза кишечника у больных хроническим гастродуоденитом, ассоциированным с Helicobacter pylori. Вестник СПбГМА имени И.И. Мечникова. 2006; 2: 89-92.

112. Goldman C.G., Barrado D.A., Balcarce N. et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition. 2006 Oct;22(10):984-8. doi: 10.1016/j.nut.2006.06.008.

113. Gotteland M., Brunser O., Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther. 2006 Apr 15;23(8):1077-86. doi: 10.1111/j.1365-2036.2006.02868.x.